Web19 Jan 2024 · Most evidence supporting the use of CAC in risk prediction comes from cohorts with very low rates of statin use and has mostly been used to inform guideline recommendations on personalized statin therapy allocation. 8,9 Statin therapy modestly accelerates calcification of plaques leading to more stable, lower-risk compositions and … Web6 rows · The Uniform Data System (UDS) Clinical Measures Exclusions and Exceptions resource was developed ...

Statin intolerance: why and what to do - with a focus on diabetic ...

WebMeasure total cholesterol, HDL-C and non-HDL-C in all people on high-intensity statin at 3 months of treatment and once stable annually. LFTs: Measure ALT within 3 months of starting treatment and at 12 months, but not again unless clinically indicated. Do not routinely exclude from statin therapy people who have an ALT that is raised but less WebMembers who remained on a statin medication of any intensity for at least 80% of the treatment period. Best Practice and Measure Tips. The treatment period is defined as the earliest prescription dispensing date in the measurement year for any statin medication of at least moderate intensity through the last day of the measurement year. christopher fillmore

2024 UDS Clinical Measures Exclusions and Exceptions

WebThe UDS includes tables that provide consistent demographic, clinical, operational, and financial data. View national aggregated summaries of UDS health center awardee data. For more detailed descriptions of UDS tables, visit the UDS Resources page to access UDS manuals and other reporting documentation. View Full 2024 National Report. WebThe standards of medical care in diabetes recommend that statin therapy is added to lifestyle therapy for diabetic patients with overt cardiovascular disease (LDL cholesterol goal <70 mg/dl), or without cardiovascular disease who are over the age of 40 years and who have one or more other cardiovascular disease risk factors (LDL cholesterol goal … WebFactors such as polypharmacy, frailty, and comorbidities should be taken into account before starting statin therapy. A Strength of recommendation: High NICE (2016) recommends low-dose atorvastatin for patients who have a 10% or greater 10-year risk of developing CVD (using the QRISK2 calculator), and for patients with chronic kidney disease. getting no showings 10% priced too high